Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $133 | $128 | $112 | $99 |
| % Growth | 4.1% | 14.5% | 12.2% | – |
| Cost of Goods Sold | $26 | $23 | $23 | $23 |
| Gross Profit | $107 | $104 | $89 | $77 |
| % Margin | 80.8% | 81.7% | 79.4% | 77.1% |
| R&D Expenses | $43 | $46 | $46 | $44 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $62 | $63 | $58 | $57 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $105 | $109 | $104 | $101 |
| Operating Income | $3 | -$5 | -$15 | -$24 |
| % Margin | 2% | -3.9% | -13.6% | -24.4% |
| Other Income/Exp. Net | $0 | -$0 | $2 | -$0 |
| Pre-Tax Income | $3 | -$5 | -$14 | -$24 |
| Tax Expense | -$0 | $0 | $1 | -$1 |
| Net Income | $3 | -$6 | -$15 | -$24 |
| % Margin | 2.2% | -4.6% | -13.2% | -23.9% |
| EPS | 0.057 | -0.12 | -0.3 | -0.49 |
| % Growth | 147.8% | 60% | 38.8% | – |
| EPS Diluted | 0.05 | -0.12 | -0.3 | -0.49 |
| Weighted Avg Shares Out | 58 | 50 | 49 | 48 |
| Weighted Avg Shares Out Dil | 57 | 50 | 49 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $3 | $3 |
| Interest Expense | $0 | $4 | $4 | $4 |
| Depreciation & Amortization | $6 | $6 | $6 | $6 |
| EBITDA | $9 | $4 | -$4 | -$15 |
| % Margin | 6.8% | 3.3% | -3.6% | -14.8% |